Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

ucb pharma s.a. - lacosamide - epilepsies, partial - antiepileptics, - lacosamide ucb is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.,

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

ucb pharma limited - isosorbide dinitrate - concentrate for soln for inf - 0.1 %w/v

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

ucb pharma limited - isosorbide dinitrate - solution for infusion - 0.05 %w/v

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - levetiracetam, quantity: 1000 mg - tablet, film coated - excipient ingredients: macrogol 6000; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - keppra (film coated tablets and oral solution) is indicated for - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation, - monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. - add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and - add on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige). keppra concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - levetiracetam, quantity: 500 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; macrogol 6000; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - keppra (film coated tablets and oral solution) is indicated for - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation, - monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. - add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and - add on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige). keppra concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - levetiracetam, quantity: 250 mg - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; macrogol 6000; colloidal anhydrous silica; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - keppra (film coated tablets and oral solution) is indicated for - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation, - monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. - add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and - add on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige). keppra concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

ucb (pharma) ireland limited - cetirizine dihydrochloride - film-coated tablet - 10 milligram(s) - piperazine derivatives; cetirizine - piperazine derivatives - in adults and paediatric patients 6 years and above: cetirizine is indicated for the relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis. cetirizine is indicated for the relief of symptoms of chronic idiopathic urticaria.

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

ucb pharma ltd - hydroxyzine hydrochloride - oral tablet - 25mg

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

ucb pharma ltd - hydroxyzine hydrochloride - oral solution - 2mg/1ml

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

ucb pharma ltd - codeine phosphate; paracetamol - oral capsule - 30mg ; 500mg